Table 1.
Patient characteristics at baseline.
| Donor FMT |
Placebo FMT |
|
|---|---|---|
| (n = 22) | (n = 24) | |
| Sex | ||
| Men | 15 (68.2%) | 14 (58.3%) |
| Women | 7 (31.8%) | 10 (41.7%) |
| Age (years) | 61 (1.1) | 60.5 (0.7) |
| Duration since Parkinson's disease diagnosis (years) | 4.2 (0.7) | 4.4 (0.7) |
| MDS-UPDRS part 3 off medication | 40.3 (2.7) | 37.1 (2.5) |
| Hoehn and Yahr stage 2 off medication | 22 (100%) | 24 (100%) |
| Levodopa-equivalent daily dose (mg) | 383 (53) | 431 (51) |
| Body mass index (kg/m³) | 24.6 (0.8) | 24.3 (0.8) |
| MoCA score | 27.6 (0.3) | 28.2 (0.3) |
| Constipation | ||
| Constipation (ROME-IV criteria) | 14 (63.3%) | 15 (62.5%) |
| Number of radiopaque pellets on day 7 | 20.6 (2.0) | 18.6 (2.1) |
| Bristol stool chart score | 3.4 (1.1) | 3.0 (0.9) |
| 16-item sniffing sticks identification test | 7.9 (0.6) | 7.1 (0.5) |
| RBDSQ >5 points | 6 (27.3%) | 5 (20.8%) |
| Orthostatic hypotension | 9 (40.9%) | 7 (29.2%) |
Data are n (%) or mean (SEM). MDS-UPDRS, Movement Disorders Society Unified Parkinson's Disease Rating Scale. MoCA, Montreal Cognitive Assessment. RBDSQ, REM Sleep Behavior Disorder Screening Questionnaire.